Amgen in talks with FDA over Epogen, Aranesp safety labels

12/7/2007 | Reuters

California-based Amgen said it is working with the FDA to decide whether to revise warning labels on anemia drugs Aranesp and Epogen, in view of two studies that reported more deaths and incidence of tumor growth in breast and cervical cancer patients taking the drugs. The treatments already carry "black box" warnings about their link to a higher risk of death, heart attack, stroke and cancer progression.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA